PATENT CLAIM ANALYSIS

Application Number: 15997438
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "262100"]

Abstract:
The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.

Claim (Index 38):
A method of treatment for psychotic symptoms selected from hallucinations, paranoid or bizarre delusions and disorganized speech and thinking in psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusionsal disorder, mania or bipolar disorder comprising administering an effective amount of a PDE 1 inhibitor to a patient in need thereof wherein the PDE 1 inhibitor is: in free or salt form, including its enantiomers, diastereoisomers and racemates.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 94.0
- Lexical Diversity: 1.36667
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13319807', '15263256', '12517945', '12514712', '13486264']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7651811948215653
- 35 USC 102 Novelty (BERT): 0.5911079643180567
- Combined Prediction Score: 0.7477738717712146
- Mean Citation Score: 418.093732
- Max Citation Score: 479.29242
- Similarity Product: 469.75591777179113

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test